HL
Therapeutic Areas
Fortitude Biomedicines Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Lead Immune Cell Targeting Program | Autoimmune Disease (Undisclosed) | Preclinical |
| GLUE-DAC™ Platform Pipeline | Oncology & Autoimmune Diseases | Discovery/Preclinical |
Leadership Team at Fortitude Biomedicines
KD
Keith Dewedoff
Acting Chief Financial Officer
SM
Stephen Monks, Ph.D.
Acting Chief Development Officer
JT
Jan Theunissen, Ph.D.
Vice President, Discovery
MH
Matthew Huggins, Ph.D.
Principal Scientist, Immunology
WN
Wendi Ni
Director, Operations and Corporate Development